Duchenne Muscular Dystrophy how to diagnose in adults
Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. Although it is typically diagnosed in childhood, some individuals remain undiagnosed until adulthood, either due to mild symptoms or late-onset progression. Diagnosing DMD in adults requires a comprehensive and nuanced approach, combining clinical evaluation with advanced diagnostic tools to distinguish it from other muscular dystrophies and neuromuscular conditions.
The initial step in diagnosing Duchenne muscular dystrophy involves a detailed medical history and physical examination. Clinicians look for signs such as muscle weakness predominantly affecting proximal muscles, difficulty with activities like climbing stairs, rising from the floor, or lifting objects. In adults, the presentation might be subtle or atypical, often mistaken for other neuromuscular disorders, which underscores the importance of thorough history-taking, including family history and previous health records.
Electromyography (EMG) is a valuable diagnostic tool that assesses electrical activity in muscles. In DMD, EMG typically reveals a pattern of myopathic changes characterized by small, short-duration motor unit potentials. While EMG can confirm muscle involvement, it cannot definitively distinguish DMD from other myopathies, making further testing necessary.
Serum creatine kinase (CK) levels are usually markedly elevated in individuals with DMD, often five to 50 times above normal. Elevated CK indicates muscle fiber damage but is not specific for DMD. However, persistent high CK levels in adults with muscle weakness should prompt further investigation into dystrophinopathies.
Molecular genetic testing has become the cornerstone of DMD diagnosis in adults. Techniques such as multiplex ligation-dependent probe amplification (MLPA) or next-generation sequencing (NGS) are employed to detect deletions, duplications, or point mutations in the dystrophin gene. Identifying a pathogenic mutation confirms the diagnosis and helps differentiate DMD from Becker muscular dystrophy (a milder allelic form). In cases where genetic testing is inconclusive, muscle biopsy remains an important diagnostic tool.
Muscle biopsy provides histological evidence of dystrophic changes, such as fiber size variability, increased connective tissue, and degeneration/regeneration cycles. Immunohistochemical staining for dystrophin protein is particularly informative; in DMD, dystrophin expression is either absent or markedly reduced. This method not only confirms the diagnosis but also helps rule out other muscular dystrophies.
In adults, the diagnosis of DMD may be complicated by overlapping symptoms with other neuromuscular diseases, age-related muscle decline, or secondary complications. Therefore, a multidisciplinary approach involving neurologists, geneticists, and physiotherapists is essential. Additionally, genetic counseling is recommended for affected individuals and their families to understand inheritance patterns and reproductive options.
In conclusion, diagnosing Duchenne muscular dystrophy in adults involves a combination of clinical assessment, laboratory tests, genetic analysis, and muscle biopsy when necessary. Early and accurate diagnosis is vital for managing symptoms, anticipating disease progression, and exploring emerging therapeutic options.